<DOC>
	<DOC>NCT02873767</DOC>
	<brief_summary>This study is designed to evaluate the safety and tolerability of single ascending doses of UCB4019 administered by subcutaneous injection in healthy subjects.</brief_summary>
	<brief_title>A First-In-Human Study With a Single Dose UCB4019 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Good physical and mental health At least 18 and less than 65 years of age Female subjects of childbearing potential must agree to use a highly effective method of birth control, during the study and for a period of 3 months after their last dose of study drug Total Immunoglobulin G &lt;7 g/L or &gt;16 g/L at the Screening Visit Absolute neutrophil count &lt;1.5x10^9/L and/or lymphocyte count &lt;1.0x10^9/L Known viral hepatitis, has a positive test for Hepatitis B surface antigen or is Hepatitis C virus antibody positive Positive test to Human Immunodeficiency Virus (HIV) 1/2 antibodies Past medical history or family history of primary immunodeficiency Evidence of latent/active Tuberculosis (TB) Active infection or a serious infection within 6 weeks before the first dose of IMP Renal impairment Hepatic impairment Vaccination within 6 weeks before the Screening Visit or intent to have a vaccination before Day 43 of the Safety Followup Period Subject is splenectomized received any IMP or experimental procedure within 90 days before the first dose of IMP received UCB7665 in a clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>First in human</keyword>
	<keyword>Healthy volunteers</keyword>
</DOC>